CIK 0001787400
- Non-accelerated filer
- Smaller reporting company
Nkarta, Inc.
Sign in to watch- Ticker
- NKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 474515206
- Phone
- +1 925-407-1049
- Business address
- 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-14 | Mahmood Nadir | Exercise or conversion | +3,083 | $3.89 | $12K | 31,488 |
| 2021-01-14 | Mahmood Nadir | Exercise or conversion · Stock Option (right to buy) | −3,083 | 49,322 | ||
| 2021-01-08 | Rajangam Kanya Chief Medical Officer | Grant or award · Stock Option (right to buy) | +52,500 | 52,500 | ||
| 2021-01-08 | HASTINGS PAUL J Chief Executive Officer | Grant or award · Stock Option (right to buy) | +157,500 | 157,500 | ||
| 2021-01-08 | Mahmood Nadir | Grant or award · Stock Option (right to buy) | +52,500 | 52,500 | ||
| 2021-01-08 | Hager Alicia J. Chief Legal Officer | Grant or award · Stock Option (right to buy) | +13,125 | 13,125 | ||
| 2021-01-08 | Trager James Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +52,500 | 52,500 | ||
| 2020-12-03 | Mahmood Nadir | Exercise or conversion | +3,000 | $3.89 | $12K | 28,405 |
| 2020-12-03 | Mahmood Nadir | Exercise or conversion · Stock Option (right to buy) | −3,000 | 52,405 | ||
| 2020-10-26 | Hager Alicia J. Chief Legal Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2020-10-02 | Mahmood Nadir | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2020-10-02 | Mahmood Nadir | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2020-07-14 | GLAXOSMITHKLINE PLC Director | Conversion | +79,090 | 79,090 | ||
| 2020-07-14 | GLAXOSMITHKLINE PLC Director | Conversion | +525,499 | 604,589 | ||
| 2020-07-14 | GLAXOSMITHKLINE PLC Director | Conversion | +1,712,810 | 2,317,399 | ||
| 2020-07-14 | GLAXOSMITHKLINE PLC Director | Purchase | +833,333 | $18.00 | $15.0M | 3,150,732 |
| 2020-07-14 | GLAXOSMITHKLINE PLC Director | Conversion · Series A Preferred Stock | −292,663 | 0 | ||
| 2020-07-14 | GLAXOSMITHKLINE PLC Director | Conversion · Series A Preferred Stock | −1,994,348 | 0 | ||
| 2020-07-14 | GLAXOSMITHKLINE PLC Director | Conversion · Series B Preferred Stock | −6,337,403 | 0 | ||
| 2020-07-14 | GLAXOSMITHKLINE PLC Director | Grant or award · Stock Option (right to buy) | +10,700 | 10,700 |
Page 15 of 19 · 364 trades